|
LIVE WEBINAR: Thursday, February 18, 2021, 5:00 PM – 6:00 PM Eastern Time
What Clinicians Want to Know: Understanding the Factors Affecting the Optimal Diagnosis and Management of Ovarian CancerA CME-MOC/NCPD Accredited Virtual EventAccreditation and Credit Designation Statements NCPD: Research To Practice is accredited as a provider of nursing continuing professional development (NCPD) by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This educational activity for 1 contact hour is provided by Research To Practice. This activity is awarded 1 ANCC pharmacotherapeutic contact hour. AANP: This activity is approved for 1.0 contact hour(s) of continuing education (which includes 1 hour of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21014718. This activity was planned in accordance with AANP Accreditation Standards and Policies. AAPA: This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit™. PAs should claim only the credit commensurate with the extent of their participation. Approval is valid from 2/18/2021 to 2/18/2022. AAPA reference number: CME-201950. Faculty
Michael J Birrer, MD, PhD
Director, Winthrop P Rockefeller Cancer Institute University of Arkansas for Medical Sciences Little Rock, Arkansas Kathleen Moore, MD The Virginia Kerley Cade Endowed Chair in Cancer Development Associate Director, Clinical Research Director, Oklahoma TSET Phase I Program Stephenson Cancer Center Associate Professor, Section of Gynecologic Oncology Director, Gynecologic Oncology Fellowship Department of Obstetrics and Gynecology University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma David M O'Malley, MD Professor Division Director, Gynecologic Oncology Co-Director, Gynecologic Oncology Phase I Program The Ohio State University and The James Cancer Center Columbus, Ohio Moderator Neil Love, MD Research To Practice Miami, Florida Topics to Be Discussed
Target Audience
Accreditation Statements RTP designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity. NCPD Credit Designation Statements This educational activity for 1 contact hour is provided by RTP. This activity is awarded 1 ANCC pharmacotherapeutic contact hour. To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. The credit form links will be emailed to participants within 5 business days of the activity. American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Webinars/OvarianCancer2021/Feb18/ILNA AAPA: This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit™. PAs should claim only the credit commensurate with the extent of their participation. Approval is valid from 2/18/2021 to 2/18/2022. AAPA reference number: CME-201950. Unlabeled/Unapproved Uses Notice There is no implied or real endorsement of any product by Research To Practice, the ACCME, ANCC, AANP or AAPA. Any off-label use as declared by the FDA will be identified. Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/NCPD/AANP/AAPA activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Birrer — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: OncoQuest Pharmaceuticals Inc (QPT-ORE-005), VBL Therapeutics (VB-111-701/GOG-3018). Dr Moore — Consulting Agreements: Aravive Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Sorrento Therapeutics, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Contracted Research: PTC Therapeutics, US Department of Defense. Dr O'Malley — Advisory Committee and Consulting Agreements (Personal Fees): AbbVie Inc, Agenus Inc, Ambry Genetics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Rubis, Seagen Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Contracted Research (All Funding to Institution): AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, National Cancer Institute, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc, Yale University; Contracted Research (Personal Fees): Clovis Oncology, Mersana Therapeutics; Data and Safety Monitoring Board/Committee: Watermark Research Partners Inc.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc. Research To Practice CME/NCPD/AANP/AAPA Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck. |